RALLYBIO CORPORATION Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
RALLYBIO CORPORATION (RLYB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.50 million for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-08-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-08-26
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $2.50M S-4/A · filed 2026-08-26 |
| 2024-12-31 | $19.70M S-4/A · filed 2026-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |